Global pharmaceutical leader Lupin Limited announced that its greenhouse gas (GHG) emissions reduction targets were officially validated by the Science Based Targets initiative (SBTi).

This validation confirms that Lupin's climate goals align with the Paris Agreement's 1.5°C pathway, placing the company among an elite group to achieve comprehensive validation across all three scopes within one year of target-setting.

Lupin has committed to the following science-based reductions:

Scope 1 and 2 Emissions: Reduce absolute greenhouse gas emissions by 42.0% by FY 2030, using FY 2023 as the base year.

Scope 3 Emissions: Reduce emissions by 61.07% by FY 2033, using FY 2024 as the baseline.

These goals are aligned with the 1.5°C pathway and validated under SBTi's latest guidelines, thereby positioning Lupin as a key participant in the global effort to combat climate change.

Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin, said, "The validation from SBTi underscores Lupin's unwavering commitment to reducing greenhouse gas emissions through a rigorous, science-driven approach. By setting ambitious targets, we are embedding sustainability into both our financial and operational strategies. These goals guide investments in renewable energy, energy efficiency, and low-carbon technologies across our global operations. Proactive action on climate change is essential not only for mitigating risks and optimising costs but also for unlocking opportunities for innovation and long-term growth."